欢迎来到天天文库
浏览记录
ID:53725869
大小:182.55 KB
页数:2页
时间:2020-04-20
《雷帕霉素联合顺铂治疗人骨肉瘤的研究.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、中华实验外科杂志2013年5月第30卷第5期ChinJExpSurg,May2013,Vo1.30,N0.5·1027··实验研究·雷帕霉素联合顺铂治疗人骨肉瘤的研究马俊杰皮国富刘宏建孙建广孙若宾【摘要】目的比较雷帕霉素联合顺铂与单用雷帕霉素或单用顺铂对人骨肉瘤细胞增殖和凋亡的影响。方法将人骨肉瘤细胞株随机分为4组:空白组、阳性药1组、阳性药2组和治疗组。阳性药1组应用雷帕霉素20mg/L,阳性药2组应用顺铂10mg/L,治疗组联合雷帕霉素20m#L和顺铂10mg/L,空白组加入等量生理盐水。利用噻唑蓝(MTT)比色法检测雷帕霉素联合顺铂或单用霄帕霉素顷铂对骨肉瘤细胞的增殖抑制率;流式
2、细胞术检测雷帕霉素联合顺铂或单川雷帕霉素/Jl_而铂对骨肉瘤细胞凋亡率的影响。结果联合应用两种药物对人骨肉瘤的抑制牢较单独使用明显增强,且差异有统计学意义(P3、reatmentofrapamycincombinedwithcisplatinMAJunqie,PIGuo-fu,HUHong4ianSUNJian—guangSUNRuo—bin.DepartmentofOrthopeadicstheFirstAffliatedHospitalofZhengzhouUniversity.Zhengzhou450052.inaCorrespondingauthor:P1&o-fit,Email:gfpi2217@yahoo.coin.cn【Abstract】0bjectiveBythecomparisionoftherapamycincombined4、withcisplatinwiththerapa—mycinorcisplatinalonetowardsosteosareoma’sproliferationandapoptosis.toprovidenewlnetho(1intrea—tingosteosareomaintheclinica1.MethodsBonesarcomacell1inewererandomlydividedinto4groups:Theblankgroup,positivemedicinegroup1,positivemedicinegroup2andthetreatmentgroup.toadd20mL5、rapamycininthepositivemedicinegroup1,toadd10nlg/LcisplatinInthepositivemedicinegroup2,toadd20ing/Lrapamycinand10rElg/Lcisplatininthetreatmentgroup,andtoaddtheequalamountofnormalsalineintheblankgroup.ThendetecttheInhibitionrateofeverygroupwithMMT,andtheap—optosisratewithflowcytometry.Resuhstomean6、±standarddeviationf叠±s1said.ResultsTheinhibi—tionrateandapoptosisrateofcombinationtowardsosteosarcomaenhancesobviouslycomparedtothesepa—rateapplication,andthedifferenceisstatisticallysignificant(P<0.05).Theblankgroup:0.33±0.02,positivemedicinegroupl:0.56±0.05,positivemedicinegroup2:0.55±0.03,The7、treatmentgroup:0.95±0.01.Theapoptosisrateofeombinationtowardsosteosarcomaenhancesobviouslycomparedtotheseparateapplication,andthedifferenceisstatisticallysignificant(P<0.05).ConclusionThecombina—tionofrapamycinandcisplatinca
3、reatmentofrapamycincombinedwithcisplatinMAJunqie,PIGuo-fu,HUHong4ianSUNJian—guangSUNRuo—bin.DepartmentofOrthopeadicstheFirstAffliatedHospitalofZhengzhouUniversity.Zhengzhou450052.inaCorrespondingauthor:P1&o-fit,Email:gfpi2217@yahoo.coin.cn【Abstract】0bjectiveBythecomparisionoftherapamycincombined
4、withcisplatinwiththerapa—mycinorcisplatinalonetowardsosteosareoma’sproliferationandapoptosis.toprovidenewlnetho(1intrea—tingosteosareomaintheclinica1.MethodsBonesarcomacell1inewererandomlydividedinto4groups:Theblankgroup,positivemedicinegroup1,positivemedicinegroup2andthetreatmentgroup.toadd20mL
5、rapamycininthepositivemedicinegroup1,toadd10nlg/LcisplatinInthepositivemedicinegroup2,toadd20ing/Lrapamycinand10rElg/Lcisplatininthetreatmentgroup,andtoaddtheequalamountofnormalsalineintheblankgroup.ThendetecttheInhibitionrateofeverygroupwithMMT,andtheap—optosisratewithflowcytometry.Resuhstomean
6、±standarddeviationf叠±s1said.ResultsTheinhibi—tionrateandapoptosisrateofcombinationtowardsosteosarcomaenhancesobviouslycomparedtothesepa—rateapplication,andthedifferenceisstatisticallysignificant(P<0.05).Theblankgroup:0.33±0.02,positivemedicinegroupl:0.56±0.05,positivemedicinegroup2:0.55±0.03,The
7、treatmentgroup:0.95±0.01.Theapoptosisrateofeombinationtowardsosteosarcomaenhancesobviouslycomparedtotheseparateapplication,andthedifferenceisstatisticallysignificant(P<0.05).ConclusionThecombina—tionofrapamycinandcisplatinca
此文档下载收益归作者所有